Abstract:Farnesoid X receptor (FXR) agonists can reverse dysregulated bile acid metabolism, and thus, they are potential therapeutics to prevent and treat nonalcoholic fatty liver disease. The low success rate of FXR agonists' R&D and the side effects of clinical candidates such as obeticholic acid make it urgent to discover new chemotypes. Unfortunately, structure-based virtual screening (SBVS) that can speed up drug discovery has rarely been reported with success for FXR, which was likely hindered by the failure in addressing protein flexibility. To address this issue, we devised human FXR (hFXR)-specific ensemble learning models based on pose filters from 24 agonist-bound hFXR crystal structures and coupled them to traditional SBVS approaches of the FRED docking plus Chemgauss4 scoring function. It turned out that the hFXR-specific pose filter ensemble (PFE) was able to improve ligand enrichment significantly, which rendered 3RUT-based SBVS with its PFE the ideal approach for FXR agonist discovery. By screening of the Specs chemical library and in vitro FXR transactivation bioassay, we identified a new class of FXR agonists with compound XJ034 as the representative, which would have been missed if the PFE was not coupled. Following that, we performed in-depth biological studies which demonstrated that XJ034 resulted in a downtrend of intracellular triglyceride in vitro, significantly decreased the serum/liver TG in high fat diet-induced C57BL/6J obese mice, and more importantly, showed metabolic stabilities in both plasma and liver microsomes. To provide insight into further structure-based lead optimization, we solved the crystal structure of hFXR complexed with compound XJ034, uncovering a unique hydrogen bond between compound XJ034 and residue Y375. The current work highlights the power of our pose filter-based ensemble learning approach in terms of scaffold hopping and provides a promising lead compound for further development.

[Progress in the Ligands and Their Complex Structures of Farnesoid X Receptor].

Machine learning- and structure-based discovery of a novel chemotype as FXR agonists for potential treatment of nonalcoholic fatty liver disease

Natural Products in the Modulation of Farnesoid X Receptor Against Nonalcoholic Fatty Liver Disease

Farnesoid X receptor modulators 2014-present: a patent review

Design, synthesis and biological evaluations of novel farnesoid X receptor (FXR) agonists

Pose Filter-Based Ensemble Learning Enables Discovery of Orally Active, Nonsteroidal Farnesoid X Receptor Agonists

FXR: structures, biology, and drug development for NASH and fibrosis diseases

Farnesoid X Receptor (FXR): Structures and Ligands.

[Progress in the Role of Farnesoid X Receptor in Metabolic Regulation and Tumor Cell Proliferation].

Progression in the study on roles of farnesoid X receptor

Farnesoid X Receptor Agonists as Therapeutic Target for Cardiometabolic Diseases

Recent Advances in Non-Steroidal FXR Antagonists Development for Therapeutic Applications

3D-QSAR and Molecular Dynamics Study of Isoxazole Derivatives to Identify the Structural Requirements for Farnesoid X Receptor (FXR) Agonists

Discovery of New Non‐Steroidal Farnesoid X Receptor Modulators Through 3D Shape Similarity Search and Structure‐Based Virtual Screening

Update on FXR Biology: Promising Therapeutic Target?

Role of Farnesoid X Receptor in Regulating Lipid Metabolism

Discovery of novel and selective farnesoid X receptor antagonists through structure-based virtual screening, preliminary structure-activity relationship study, and biological evaluation

Structural insights into the heterodimeric complex of the nuclear receptors FXR and RXR

Farnesoid X receptor gene polymorphisms and metabolic disease

Farnesoid X receptor: a potential therapeutic target in multiple organs

Design, Synthesis, and Biological Evaluation of Novel Nonsteroidal Farnesoid X Receptor (FXR) Antagonists: Molecular Basis of FXR Antagonism.